Pages that link to "Item:Q2482986"
From MaRDI portal
The following pages link to Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model (Q2482986):
Displaying 11 items.
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy (Q2001894) (← links)
- Identification of causal effects within principal strata using auxiliary variables (Q2075703) (← links)
- Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433) (← links)
- Augmented Designs to Assess Principal Strata Direct Effects (Q3107200) (← links)
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling (Q3119801) (← links)
- A Bayesian Approach to Improved Estimation of Causal Effect Predictiveness for a Principal Surrogate Endpoint (Q4649074) (← links)
- A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework (Q4984852) (← links)
- A unified evaluation of differential vaccine efficacy (Q6047741) (← links)
- Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy (Q6055756) (← links)
- Surrogacy validation for time-to-event outcomes with illness-death frailty models (Q6625395) (← links)
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials (Q6636037) (← links)
